The Daily Fuckup

The Food and Drug Administration’s emergency authorization of hydroxychloroquine sulfate and chloroquine phosphate on March 28 was written like a narrow regulatory move, but it arrived in a political environment that had already turned both drugs into a national obsession. The agency said the products, drawn from the Strategic National Stockpile, could be used for certain hospitalized COVID-19 patients when a clinical trial was not available or was not feasible. That language mattered, because emergency use authorization is not the same thing as a declaration that a drug has been proven safe or effective for a new disease. It is a legal tool meant to help government respond when a public health crisis leaves officials without enough time or enough evidence to wait for the usual process to finish. In ordinary circumstances, those distinctions would be clear enough. In late March 2020, with the president publicly touting hydroxychloroquine as if it were already a breakthrough, the line between limited permission and broad endorsement was already in danger of collapsing.

That collapse is the real story here. The FDA did not say the drugs worked, but the timing and the political climate made it easy for people to hear the announcement as proof that the government had effectively signed off on the president’s message. The authorization could be defended as an attempt to give doctors another option while trials were being organized or while some hospitals had no realistic way to enroll patients in them. It also reflected a grim reality of the early pandemic: regulators were being forced to make decisions under pressure, with incomplete information, and in an atmosphere that rewarded speed over caution. But once hydroxychloroquine had been elevated into a presidential talking point, the FDA’s action could no longer be treated as a purely technical matter. It became a public signal that the White House could use to suggest the science was catching up to the political script. That is not a trivial communications problem. It is exactly the kind of misunderstanding that can distort how the public reads risk, evidence, and uncertainty.

The danger is not just that people may confuse emergency authorization with a scientific conclusion. It is that the authorization can be folded back into the political narrative and used to reinforce a false sense of certainty. In a pandemic, many people are desperate for a treatment that sounds like it might change the equation, and that desperation makes them vulnerable to overselling from officials who want to project control. Once a federal agency opens the door, even narrowly, the public can easily mistake that door for an announcement that the answer has been found. The hydroxychloroquine rush had already begun to operate that way, with the drug discussed less as a candidate for careful study than as a shortcut to normal life. The FDA’s emergency move, however limited on paper, risked hardening that perception into something closer to conventional wisdom. That is especially dangerous because emergency use authorization exists precisely to allow action before the evidence is complete, not after it has been settled. If the public cannot tell those ideas apart, then the regulatory framework stops informing people and starts misleading them. Doctors need room to think in evidence-based terms, not in slogans. Patients need to know the difference between a treatment being tried and a treatment being proven. The public needs to understand that federal permission is not the same thing as scientific certainty.

That is why the hydroxychloroquine episode already looked less like a solution than a warning sign. The country was entering a frightening and fast-moving crisis, and it was entirely understandable that people would cling to anything that sounded hopeful. But public institutions are supposed to resist that instinct, not amplify it. The FDA may have had defensible reasons for acting, especially given the limited options available and the possibility that some hospitalized patients might benefit from access under extraordinary conditions. Still, defensible is not the same as harmless. By moving after the president had already spent days hyping the drugs, the agency risked laundering ambiguity through official authority. That could mislead patients, doctors, and the broader public into believing the government had crossed from provisional permission into confirmation of benefit. In a normal policy debate, that would be a frustrating misunderstanding. In a pandemic, it can shape treatment choices, influence expectations, and distort how citizens understand the state of the science. The broader problem is not that the FDA acted in a vacuum. It is that politics had already turned a medical unknown into a political object, and once that happened, even a carefully bounded authorization could be made to look like a verdict. That is a dangerous way to run public health, and the risk was visible the moment the announcement was made.